Cilostazol Treatment for Intermittent Claudication in Peripheral Artery Disease

Introduction to Cilostazol

• The American College of Cardiology recommends Cilostazol 100 mg orally twice daily as the treatment for patients with intermittent claudication due to peripheral artery disease (PAD), which significantly improves walking distance by 40-60% after 12-24 weeks of therapy 1, 2, 3

Dosage and Efficacy

• Cilostazol should be administered at 100 mg orally twice daily, which is more effective than the 50 mg twice daily dosage, as recommended by the American College of Cardiology 1, 4
• Cilostazol improves both pain-free walking distance (by 59%) and maximal walking distance (by 40-60%) in patients with intermittent claudication, according to the American College of Cardiology 1

Mechanism and Effects

• Cilostazol is a phosphodiesterase type 3 inhibitor that has antiplatelet and vasodilatory effects, as described by the American College of Cardiology 1
• It produces a modest increase in ankle-brachial index (ABI), but this hemodynamic effect cannot fully account for the improvement in claudication symptoms, as noted by the American College of Cardiology 1

Important Contraindications

• Cilostazol is absolutely contraindicated in patients with heart failure of any severity due to its phosphodiesterase inhibitor properties, as stated by the American College of Cardiology 1, 5

Treatment Algorithm

• The American College of Cardiology recommends supervised exercise training (30-45 minutes, at least 3 times weekly for minimum 12 weeks) as first-line therapy for intermittent claudication 2, 3
• The American College of Cardiology recommends Cilostazol 100 mg twice daily for all patients with lifestyle-limiting claudication without heart failure 1, 2, 3

Alternative Medications

• Pentoxifylline (400 mg three times daily) may be considered as a second-line alternative to cilostazol, but its clinical effectiveness is marginal and not well established, according to the American College of Cardiology 1, 2, 3

Safety Profile

• Approximately 20% of patients discontinue cilostazol within 3 months due to side effects, as reported by the American College of Cardiology 5

Clinical Pearls and Pitfalls

• The American College of Cardiology advises to always assess for heart failure before prescribing cilostazol, as it is contraindicated in these patients 1, 5
• The American College of Cardiology suggests that combination therapy with exercise and cilostazol may provide additive benefits for patients with claudication 2, 3